Thirteen Departments Jointly Formulated an Action-implementation Plan for Cancer Prevention and Control from 2023 to 2030

​A total of 13 departments, including the National Health Commission (NHC) and the National Development and Reform Commission (NDRC) have jointly formulated an action-implementation plan for cancer prevention and control from 2023 to 2030, with the main goals being to further improve the cancer care system and make the overall 5-year cancer survival rate reach 46.6% by 2030, a move to further implement the strategy of a healthy China.

The specific measures of the action plan include promoting occupational cancer prevention and control, sharing of relevant information resources, early diagnosis and treatment, and enhancing the capacity for cancer care by using traditional Chinese medicine, as well as strengthening the promotion and application of cancer research achievements.

In terms of promoting early diagnosis and treatment of cancer, the action plan requires all regions to publish guidelines for key cancers, such as gastric cancer, esophageal cancer, colorectal cancer, cervical cancer, breast cancer and lung cancer, which have a high incidence rate and are relatively mature in terms of diagnostic methods. To gradually expanding the coverage of screening and early diagnosis and treatment, targeting cancers that have a high incidence, are cost-effective for early treatment, and for which screening methods are simple to implement. To organize screening continuously in areas with high cancer incidence and among high-risk groups.

The early cancer screening has become a hotspot in the medical device industry. According to the Analysis Report of Market Outlook and Investment Strategy Planning for Early Cancer Screening Industry, the market size of China's early cancer screening industry will be RMB 3.009 billion in 2020 and is expected to reach RMB 9.357 billion by 2025, at a CAGR of 25.6%.

For in-vitro diagnostic (IVD) companies, liquid biopsy offers a non-invasive and real-time method to detect and analyze tumor signals through body fluid samples, including blood, saliva and urine. 

Overcoming the limitations of traditional tissue biopsy, liquid biopsy provides advantages such as real-time dynamic monitoring and the ability to address tumor heterogeneity. With its user-friendly operation and relatively low cost, this innovative approach is poised to facilitate early cancer screening, particularly in remote regions and grassroots levels. 

As the application expands, the demand for associated medical devices is expected to rise, presenting companies with a strategic opportunity for new development in the ever-evolving landscape of cancer diagnostics.